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ease has been steadily rising for the past 10 years and is
projected to continue to increase in the upcoming
decade worldwide. The molecular events that ultimate-
ly result in mesothelioma are not understood, nor have
any tumor markers been identified in this disease.2,3
Until recently, no effective treatments have been
available for mesothelioma. Clinical trials have docu-
mented a response rate in the 20% range for most
chemotherapeutic agents with activity, and the majority
of patients have been treated with palliative and sup-
portive measures. With this treatment, the median sur-
vival ranged from 4 to 12 months.2,4,5 In the past
decade, a few advances have been made in the treatment
of mesothelioma. Extrapleural pneumonectomy fol-
lowed by adjuvant chemoradiation has been shown
effective in both palliation and prolongation of survival
in selected patients with mesothelioma.6,7 Furthermore,
new chemotherapeutic agents have shown a high
response rate for mesothelioma in preliminary stud-
ies.8,9 Despite the improved surgical and multimodality
M alignant pleural mesothelioma is a rare and fatalmalignancy of the pleura usually resulting from
asbestos exposure and accounting for 2500 new cases in
the United States every year.1 The incidence of this dis-
Objective: To determine whether the folate receptor gene is overexpressed in
malignant pleural mesothelioma.
Methods: Differential display analysis was performed with fresh frozen RNA
obtained from normal lung, pleura, and mesothelioma. Sixty differentially
expressed genes were identified and characterized. One gene that was over-
expressed in mesothelioma versus normal tissue was the human α folate
receptor. In situ hybridization with antisense probes designed on the basis of
the sequence of the folate receptor was performed with frozen sections from
61 patients (33 epithelial and 28 mixed or sarcomatoid tumors) with malig-
nant pleural mesothelioma. The controls included normal pleura, normal
lung, other cancers, and sense controls for all of the tumors. Northern analy-
sis with a folate receptor probe and immunohistochemical analysis with anti-
α folate receptor antibodies were also performed.
Results: Forty-four (72%) of the 61 mesothelioma tumors were found to have
between 2-fold and 4-fold higher mRNA expression of the folate receptor
when compared with the control tissues. The histologic type of the tumor did
not affect the rate of folate receptor activation. Northern analysis and
immunohistochemical experiments confirmed these findings.
Conclusions: A majority of mesothelioma tumors examined overexpress the
α folate receptor protein when compared with normal adjacent tissues. This
finding may help explain the observations that antifolate drugs have activity
in the treatment of mesothelioma. It also encourages further study of folate
receptor–related treatment strategies in this malignancy.  (J Thorac
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options for the treatment of malignant pleural mesothe-
lioma, the majority of patients will eventually die of
their disease. Most patients who undergo extrapleural
pneumonectomy will eventually have a local recur-
rence or, as they survive longer, metastatic spread.1,10
Additional modalities are required to achieve better
control of the disease both locally and systemically.
With that goal in mind, we have concentrated our
efforts on identifying how RNA expression in mesothe-
lioma tumor cells differs from that of the tissues in
which it arises, lung and pleura. We have performed
screening differential display experiments that have
identified the folate receptor gene as overexpressed in a
single patient with mesothelioma. In this article, we
evaluate the folate receptor gene expression pattern in
mesothelioma tumors.
Materials and methods
Tissues and clinical database. Frozen tumor and normal
tissue specimens were obtained from the Thoracic Oncology
Tumor Bank at the Brigham and Women’s Hospital. Surgical
specimens obtained from patients undergoing extrapleural
pneumonectomy or pleurectomy were divided into small
samples (3 × 3 × 3 mm), snap frozen, and stored at –140°C.
Normal tissues from patients with mesothelioma and tissues
from patients without mesothelioma were also collected, sim-
ilarly processed, and preserved in the tumor bank. At least
one sample adjacent to each snap-frozen sample was embed-
ded in optimal cutting temperature medium (OCT) for histo-
logic sectioning to estimate tumor cell content of the snap-
frozen sample and to provide sections for in situ hybridization
and immunohistochemistry. Slides stained with hematoxylin
and eosin were generated from OCT blocks of about 200
mesothelioma tissues in the tumor bank and reviewed by a
pathologist to identify those tumor samples that had greater
than 50% tumor cells among nucleated cells on the slide.
Eighty such tumor samples were identified, most with adja-
cent control normal tissues (lung, pleura, or skeletal muscle).
The adjacent snap-frozen samples were selected for further
study. Relevant clinical data were collected for all 80 patients
and linked to both the specimens and the patient identifier
link-ups (destroyed by the Tumor Bank staff before distribu-
tion of the tissue to this project to protect patient confiden-
tiality). Tissue collection and these experiments were per-
formed in accordance with and with the approval of the
institution’s research review board. The tissues generated as
described above with their linked clinical information were
used in the experiments presented in this report.
Differential display analysis. Normal lung, normal pleura,
and mesothelioma tumor tissues were used in the experiment.
The tissues were homogenized, and RNA was isolated with a
Qiagen extraction kit (Qiagen, Inc, Chatsworth, Calif).
Differential display polymerase chain reaction (PCR) analy-
sis was performed as described by Liang and Pardee.11,12
Sixty bands were selected that were differentially expressed
in the three tissues used above. These bands were then cut out
and purified by means of the QIAquick Gel Extraction Kit
(Qiagen, Inc). The purified bands were then re-amplified by
PCR and subcloned into the pCR-TRAP cloning vector
(GenHunter Corporation, Nashville, Tenn). All inserts were
then subjected to double-strand DNA sequencing by means
of the ABI PRISM automatic sequencer (Applied Bio-
systems, Foster City, Calif). The DNA sequences were ana-
lyzed against the Gene Bank via a Blast search
(http://www.ncbi.nlm.nih.gov).
In vitro RNA probe synthesis and fluorescent in situ
hybridization. Frozen sections 6 µm thin were prepared
from OCT tissue blocks on a Minotome cryostat
(Damon/IEC Division, Needham Heights, Mass) and stored
at –80°C until use. Samples were fixed in 4% paraformalde-
hyde for 20 hours and then treated in 30% sucrose for 16
hours at 4°C. The entire 320 base pair (bp) sequence of the α
folate receptor gene fragment (tag #37) was transcribed with
T7 and SP6 to generate both antisense and sense RNAs,
respectively. The in vitro transcription was performed with 50
ng complementary DNA, fluorescein-12-uridine-5´-triphos-
phate, and either with SP6 or T7 RNA polymerase as
described by the manufacturer (Roche Molecular
Biochemicals, Indianapolis, Ind). Subsequent manipulations
were performed, and the labeled nucleotides were separated
from the unlabeled on a Sephadex G-50 column (Gene-
Expression Systems, Inc, Waltham, Mass). Labeled RNA was
collected from these columns into an RNAse-free tube, pre-
cipitated, and finally resuspended in 50 µL of 0.1 mol/L
dithiothreitol. The concentration of RNA was measured by
spectrophotometer at 260 nm, and the concentration of fluo-
rescein label was determined at 495 nm. The processed tissue
sections were rehydrated in 70% ethanol for 10 minutes. The
slides were incubated in DNAse-free RNAse (100 µg/mL in
2 × standard sodium chloride citrate) for 1 hour at 37°C fol-
lowed by treatment with 0.2 mol/L HCl for 20 minutes. In
situ hybridization was performed with a Uni-in-situ-
GeneLock Kit (GeneExpression Systems, Inc). Normal pleu-
ra and mesothelioma tissue sections were hybridized with 10
ng denatured labeled RNA probe at 37°C for 15 hours before
performance of pre-hybridization at 37°C for 2 hours. At the
end of the hybridization, the probe was removed, and the
slides were washed under high stringent conditions. Finally,
a drop of Slow-fade reagent (Molecular Probes Inc, Eugene,
Ore) was added to the samples, which were then sealed with
nail polish and kept in the dark at 4°C until analyzed with the
Bio-Rad MRC 1024 laser based confocal microscope (Bio-
Rad Laboratories, Hercules, Calif). The resulting slides were
scored from 1 to 5 on the basis of the expression. This analy-
sis was performed for 61 different mesothelioma tissues, as
well as for three samples of normal pleura. Normal lung con-
trols samples, samples from our tumor bank, and several con-
trol tumor tissues that were purchased (Novagen, Madison,
Wis) were also analyzed.
Northern blot analysis. Total RNA (20 µg) was fraction-
ated in 2.2 mol/L formaldehyde/1.2% agarose gels, trans-
ferred to Nytran membrane (Schleicher & Schuell, Dassel,
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Germany), and hybridized as previously described.13
Hybridizations were carried out by means of the tag #37
probe, a 0.32-kilobase (kb) fragment obtained by PCR ampli-
fication from the plasmid pKA37 followed by band extrac-
tion and gel purification with Qiagen gel extraction kit
(Qiagen, Inc, US, Valencia, Calif). Human β actin cDNA
probe was prepared with the use of Human Gene Detect Kit
I (GeneExpression Systems, Inc) and used as a control. High
specific probes were generated by labeling cDNA fragments
with α-[32P] deoxycytidine triphosphate (6000 Ci/mmol),
using a random prime labeling kit (NEN/Dupont, Boston,
Mass) and hybridized as described.10 Messenger RNA tran-
script expression levels were quantitated by exposing the
probed filter to x-ray film in a Molecular Devices cassette and
further analyzed in a phosphorImager (Molecular Dynamics,
Inc, Sunnyvale, Calif).
Immunohistochemical analysis. Frozen sections 6 µm
thick were cut with a Minotome cryostat, fixed in acetone at
4°C for 10 minutes, and stored at –20°C until use. Before use,
they were brought to room temperature and washed with
phosphate-buffered saline solution (PBS) three times. The
slides were incubated in 0.3% hydrogen peroxide, which was
prepared in PBS for 10 minutes, to quench endogenous per-
oxidase activity. Two different monoclonal antibodies against
the α folate receptor, Mov18 and Mov19 (gifts of Dr S.
Canevari, National Tumor Institute, Milan, Italy), were used
as described by Mantovani and associates.14 Immuno-
histochemistry was performed with a Uni-Histochem kit
(GeneExpression Systems, Inc), and the slides were mounted
with coverslips, analyzed through a Carl Zeiss microscope
(Carl Zeiss, Inc, Thornwood, NY), and photographed. Slides
stained with trp E antibody (Oncogene Research Products,
Cambridge, Mass) to monitor the background staining were
used as controls. Sections of human fallopian tube adenocar-
cinomas, lung adenocarcinomas, uterine carcinomas, squa-
mous cell carcinomas, and normal lung and pleura were used
as positive and negative controls. The cells that immunore-
acted with the respective antibodies were counted, as were
the total tumor cells per slide, and percentages of folate
receptor expression were obtained.
Results
Differential display analyses comparing RNA
expression in fresh frozen tissues obtained from
mesothelioma, normal lung, and pleura was performed.
The mesothelioma tissue was obtained from a single
patient with epithelial subtype. Sixty differentially
expressed cDNA tags were selected for further analy-
sis. One of the 60 cDNA tags obtained from the differ-
ential display experiments, cDNA tag #37, was highly
expressed in mesothelioma only and was also noted to
have a 92% homology to the human α folate receptor
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Fig 1. The nucleotide sequence of tag #37 (A) and the representation of the sequence of the α folate receptor full
length mRNA transcript, its coding region, and sequence tag #37 (B).
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cDNA.15 Complementary DNA tag #37 covers the
entire 3´ untranslated region, as well as 117 bp of cod-
ing region in the 3´ region of the 1230-bp long cDNA
of the human α folate receptor. The cDNA tag is 320 bp
long and has a sequence nearly identical to that of the
α folate receptor transcript from base pair 907 to 1230.
The homology was 100% in the protein-coding region
from base pair 907 of the α folate receptor cDNA,
where the cDNA tag sequence commences, to base pair
1024, where the translation ends (Fig 1). Our differen-
tial display analysis suggests that the human α folate
receptor gene is represented by cDNA tag #37 and is
significantly more expressed in mesothelioma than in
adjacent normal lung or pleura.
Fluorescence in situ hybridization was used to deter-
mine the expression of cDNA tag #37 in mesothelioma.
Sixty-one different mesothelioma tissues (33 epithelial,
25 mixed, and 3 sarcomatoid) were used, as well as a
number of other tissues including 3 normal lung, 3 nor-
mal pleura, uterine carcinoma, fallopian tube adenocar-
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Fig 2. Fluorescent in situ hybridization with an antisense probe generated on the basis of the sequence of tag #37
of normal pleura (A) and normal lung (B).
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cinoma, breast carcinoma, and renal cell carcinoma.
Each tumor sample was tested twice with both a nor-
mal pleura and normal lung specimen on the same
slide. All of the slides were scored by same observer
using a scale of 1 to 5 (1 = minimal hybridization; 5 =
maximal hybridization). The pulmonary tissue controls
gave a score of 1 or 2, consistent with minimal baseline
expression of the α folate receptor in lung and pleura
(Fig 2, A and B). Most normal human tissues analyzed
had low levels of expression, as previously reported.16
Uterine cancer and human breast cancer had low levels
(scored 1 to 2), and fallopian tube adenocarcinoma (Fig
2, C) had a high level (scored 4) of expression as pre-
viously reported.16,17 Forty-four (72%) of the mesothe-
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Fig 2. Cont’d.  Fallopian tube adenocarcinoma (C) and malignant pleural mesothelioma (D).
C
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lioma tissues were scored between 3 and 5 (Fig 2, D),
and the rest scored 1 to 2. To determine whether the his-
tologic subtype of mesothelioma affected the expres-
sion level of the α folate receptor RNA, we used the
Student t test to analyze the hybridization score in the
mixed histology subgroup versus the epithelial histol-
ogy subgroup. We found no statistical difference
between the two subgroups (2-sample t [degrees of
freedom] = 0.2468, P = .8059). We also performed a
Kaplan-Meier cumulative survival analysis and found
no survival difference between the group that had ele-
vated folate receptor levels and the group that did not.
We conclude that the α folate receptor transcript is acti-
vated in a majority of mesothelioma tissues tested and
independently of histologic subtype.
We selected five of the mesotheliomas to perform
Northern analysis, three from specimens that had low
activity in the in situ hybridization experiments and two
that had elevated expression of the folate receptor. We
compared equal amounts of total RNA from these
tumors and their normal controls using the tag #37
sequence as a probe. There are 10 lanes in the Northern
blot, which are arranged as sequential adjacent normal
and tumor columns. As can be seen in Fig 3, the normal
controls have a barely recognizable band, whereas the
tumors all have a band approximately 1.3 kb in size,
which is the expected size of the α folate receptor tran-
script.15 The second lane and the seventh lane represent
tumor specimens that were overexpressed in the in situ
experiments. The Northern blot analysis, which is more
sensitive than the in situ experiments, supports the con-
clusion that the α folate receptor transcript is expressed
in elevated levels in mesothelioma relative to adjacent
normal controls, even in some tissues that do not have
very high expression in the in situ experiments.
Finally, we obtained two anti-α folate receptor mono-
clonal antibodies14,18 and used them to immunolocalize
the folate receptor on frozen mesothelioma tissues, as
well as in appropriate control tissues. Specimens
obtained from normal pleura, normal lung, uterine carci-
noma, and squamous carcinoma of the lung served as
negative controls. Specimens from fallopian tube carci-
noma and lung adenocarcinoma served as positive con-
trols.19 We have used 17 mesothelioma specimens that
were also used in the in situ experiments. As seen in Fig
4, A, there is none to minimal expression of the receptor
in normal pleural cells, but 13 of the mesothelioma
tumor samples demonstrated immunolocalization at the
cell membrane at moderate to high levels (Fig 4, B). In
15 of the 17 specimens there was complete correlation of
expression between the in situ and the immunohisto-
chemical experiments. We conclude that the α folate
receptor gene and protein are expressed in a majority of
the mesothelioma tumors that we examined at higher
levels than in adjacent normal tissues.
Discussion
The α folate receptor is a glycoprotein that is
anchored to the cell membrane of a variety of epithelial
cells. It binds folate at a high affinity and mediates its
transmembrane transport into the cytoplasm for use in
purine and pyrimidine biosynthesis.15-17,20 The α folate
receptor has been shown to be highly expressed in a
number of tumors, most significantly in ovarian carci-
noma and mesodermally derived tumor, where it has
recently been exploited for novel therapies.16,17,21 It is
also reported to be highly expressed in nasopharyngeal
carcinoma and cervical carcinoma. Franklin and col-
leagues19 performed immunohistochemical analysis on
lung cancer and demonstrated that adenocarcinomas,
but not squamous cell carcinomas, express the folate
receptor intensely. Additional studies reveal that this
receptor is not highly expressed in lung tissues, but that
it is present in type I and II pneumocytes.17 Although
the α folate receptor is not the only mediator for folate
and antifolate drug transport into the cytoplasm of
tumor cells, it can function as the major folate transport
system when expressed at high levels.17,20 The α folate
receptor gene and the other related folate receptor
genes β and χ are closely related and located on chro-
mosome 11.17 The α folate receptor transcript is 1230
bp long, and the mature protein contains 239 amino
acid residues.15
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Fig 3. Northern blot demonstrating the presence of a 1.3-kb
band (marked F on the blot) in tumor samples and nearly no
band in the adjacent normal controls. Columns 1 through 10
show alternating adjacent normal tissue and mesothelioma
tissue from 5 separate patients.
Using a nonselective method, we identified a 320 bp
mesothelioma cDNA tag that is expressed at a high
level in mesothelioma compared with normal tissues
that contain pleural mesothelial cells, pleura, and lung.
This cDNA tag has a high homology to the α folate
receptor cDNA. In fact, it is identical with the 117 bp
of the cDNA in the 3´ end of the coding sequence and
highly homologous to the 3´ untranslated region. This
gene tag is activated in 45 of 60 mesothelioma tissues
studied, regardless of histologic type. Furthermore, this
gene tag hybridizes to a 1.3 kb band in Northern blot,
and this band is activated in mesothelioma. In addition,
results of immunohistochemistry experiments per-
formed with two anti-α folate receptor antibodies veri-
fy that the folate receptor is present in mesothelioma
tumor cells at a higher level than in normal pleura and
lung cells. Our results support the conclusion that the α
folate receptor gene is highly expressed at both the
RNA and protein levels in the majority of mesothe-
lioma tissues that we have tested. To the best of our
knowledge, this article is the first report of folate recep-
tor overexpression in mesothelioma.
Folate receptor levels are elevated in a number of
other cancers, most notably in ovarian carcinoma, pre-
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Fig 4.  Immunoprecipitation with MOv 18 and Mov19 antibody on frozen section of normal pleura (A) and
mesothelioma (B). Note the localization of the antibody in the membrane and cytoplasm of the mesothelioma
tumor cells. The staining in adenocarcinoma of the lung tumor cells is positive (C) and in squamous carcinoma of
the lung is negative (D).
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sumably to avail the rapidly dividing tumor cells with
folate, which is an essential compound used for purine
and pyrimidine biosynthesis and eventually for DNA
synthesis. Acquisition of folate is essential for the
rapidly dividing cell, and its absence results in mega-
loblastosis and premature cell death. Folate can also be
transported into the cell via the reduced folate carrier,
which is a low-affinity, high-capacity transmembrane
receptor different from the high affinity α folate recep-
tor.17,20 The relative number of these two different
receptors in the cell determines which one is more
important in folate transport in a given tissue. Folate
metabolism and transport have been exploited for many
years in the pursuit of antitumor agents. Methotrexate
is a chemotherapeutic drug that is a folate analog and is
transported by both receptors. It acts by inhibiting dihy-
drofolate reductase.20 Clearly, elevated expression of
folate receptors may make mesotheliomas more sus-
ceptible to antifolate agents. It is interesting to point out
that methotrexate is one of the few agents that has had
a significant response (higher than 20%) in mesothe-
lioma.22 More recently, newer antifolate drugs such as
the multitargeted antifolates have been shown to have
significantly increased antimesothelioma activity in
clinical trials.9 Our findings are certainly in keeping
with the observed improved efficacy of antifolate drugs
in mesothelioma. Our results should encourage a more
aggressive focus on antifolates and more innovative
antifolate targeting for the treatment of patients with
malignant pleural mesothelioma. Analysis of the folate
receptor levels before chemotherapy may be useful in
selecting responders to antifolate drugs. Additional
work is required to establish the mode of internaliza-
tion of antifolate drugs and the importance of the folate
receptor overexpression in mesothelioma.
We thank Mary Visciano for editorial assistance.
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Discussion
Dr Nasser K. Altorki (New York, NY). Dr Bueno, how do
you know that you did not get nonspecific binding with your
antibody? Did you preabsorb the antibody? 
Dr Bueno. Yes, we preabsorbed to avoid nonspecific band-
ing before incubation with the antibodies. We got the same
results in the ovarian cancer–positive controls and negative
results in the tissues that were known not to express it. 
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